-
1
-
-
10244257546
-
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia
-
Baccarani M, Martinelli G, Rosti G, et al. 2004. Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia. Blood, 104:4245-51.
-
(2004)
Blood
, vol.104
, pp. 4245-4251
-
-
Baccarani, M.1
Martinelli, G.2
Rosti, G.3
-
2
-
-
33747154547
-
Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet
-
Baccarani M, Saglio G, Goldman J, et al. 2006. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood, 108:1809-20.
-
(2006)
Blood
, vol.108
, pp. 1809-1820
-
-
Baccarani, M.1
Saglio, G.2
Goldman, J.3
-
3
-
-
33645464074
-
Detection of BCR-ABL mutations and resistance to imatinib mesylate
-
Branford S, Hughes T. 2006. Detection of BCR-ABL mutations and resistance to imatinib mesylate. Methods Mol Med, 125:93-106.
-
(2006)
Methods Mol Med
, vol.125
, pp. 93-106
-
-
Branford, S.1
Hughes, T.2
-
4
-
-
0036566540
-
High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance
-
Branford S, Rudzki Z, Walsh S, et al. 2002. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood, 99:3472-5.
-
(2002)
Blood
, vol.99
, pp. 3472-3475
-
-
Branford, S.1
Rudzki, Z.2
Walsh, S.3
-
5
-
-
10744232328
-
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis
-
Branford S, Rudzki Z, Walsh, et al. 2003. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood, 102:276-83.
-
(2003)
Blood
, vol.102
, pp. 276-283
-
-
Branford, S.1
Rudzki, Z.2
Walsh3
-
6
-
-
23344440655
-
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases
-
Carter TA, Wodicka LM, Shah, et al. 2005. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA, 102:11011-16.
-
(2005)
Proc Natl Acad Sci USA
, vol.102
, pp. 11011-11016
-
-
Carter, T.A.1
Wodicka, L.M.2
Shah3
-
7
-
-
33644532202
-
SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling
-
Coluccia AM, Benati D, Dekhil, et al. 2006. SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling. Cancer Res, 66:2279-86.
-
(2006)
Cancer Res
, vol.66
, pp. 2279-2286
-
-
Coluccia, A.M.1
Benati, D.2
Dekhil3
-
8
-
-
33947356135
-
Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinibresistant or -intolerant chronic myeloid leukemia in blast crisis
-
Cortes J, Rousselot P, Kim DW, et al. 2007. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinibresistant or -intolerant chronic myeloid leukemia in blast crisis. Blood, 109:3207-13.
-
(2007)
Blood
, vol.109
, pp. 3207-3213
-
-
Cortes, J.1
Rousselot, P.2
Kim, D.W.3
-
9
-
-
2342629325
-
Imatinib (STI571) resistance in chronic myelogenous leukemia: Molecular basis of the underlying mechanisms and potential strategies for treatment
-
Cowan-Jacob SW, Guez V, Fendrich G, et al. 2004. Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment. Mini Rev Med Chem, 4:285-99.
-
(2004)
Mini Rev Med Chem
, vol.4
, pp. 285-299
-
-
Cowan-Jacob, S.W.1
Guez, V.2
Fendrich, G.3
-
10
-
-
33845444046
-
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
-
Druker BJ, Guilhot F, O'Brien SG, et al. 2006. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med, 355:2408-17.
-
(2006)
N Engl J Med
, vol.355
, pp. 2408-2417
-
-
Druker, B.J.1
Guilhot, F.2
O'Brien, S.G.3
-
11
-
-
0035810147
-
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
-
Druker BJ, Talpaz M, Resta DJ, et al. 2001. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med, 344:1031-7.
-
(2001)
N Engl J Med
, vol.344
, pp. 1031-1037
-
-
Druker, B.J.1
Talpaz, M.2
Resta, D.J.3
-
12
-
-
34247380370
-
A phase II study of Nilotinib, a novel tyrosine kinase inhibitor administered to patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who have also failed dasatinib therapy
-
Giles F, le Coutre P, Bhalla B, et al. 2006. A phase II study of Nilotinib, a novel tyrosine kinase inhibitor administered to patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who have also failed dasatinib therapy. Blood (ASH Annual Meeting Abstracts), 108:2170.
-
(2006)
Blood (ASH Annual Meeting Abstracts)
, vol.108
, pp. 2170
-
-
Giles, F.1
Coutre, P.2
Bhalla, B.3
-
13
-
-
33846240316
-
MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation
-
Giles FJ, Cortes J, Jones D, et al. 2007. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood, 109:500-2.
-
(2007)
Blood
, vol.109
, pp. 500-502
-
-
Giles, F.J.1
Cortes, J.2
Jones, D.3
-
14
-
-
20444500171
-
SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models
-
Golas JM, Lucas J, Etienne C, et al. 2005. SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models. Cancer Res, 65:5358-64.
-
(2005)
Cancer Res
, vol.65
, pp. 5358-5364
-
-
Golas, J.M.1
Lucas, J.2
Etienne, C.3
-
15
-
-
30844457497
-
Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: Does it really matter?
-
Goldman J, Gordon M. 2006. Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter? Leuk Lymphoma, 47:1-7.
-
(2006)
Leuk Lymphoma
, vol.47
, pp. 1-7
-
-
Goldman, J.1
Gordon, M.2
-
16
-
-
24644435728
-
AMN107, a novel amino- pyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia
-
Golemovic M, Verstovsek S, Giles F, et al. 2005. AMN107, a novel amino- pyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res, 11:4941-7.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 4941-4947
-
-
Golemovic, M.1
Verstovsek, S.2
Giles, F.3
-
17
-
-
13844261144
-
A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance
-
Gumireddy K, Baker SJ, Cosenza SC, et al. 2005. A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc Natl Acad Sci USA, 102:1992-7.
-
(2005)
Proc Natl Acad Sci USA
, vol.102
, pp. 1992-1997
-
-
Gumireddy, K.1
Baker, S.J.2
Cosenza, S.C.3
-
18
-
-
0038700994
-
Cytogenetic and molecular mechanisms of resistance to imatinib
-
Hochhaus A. 2003. Cytogenetic and molecular mechanisms of resistance to imatinib. Semin Hematol, 40:69-79.
-
(2003)
Semin Hematol
, vol.40
, pp. 69-79
-
-
Hochhaus, A.1
-
19
-
-
33947280081
-
Dasatinib induces notable hematologic and cytogenetic responses in chronic phase chronic myeloid leukemia after failure of imatinib therapy
-
Hochhaus A, Kantarjian HM, Baccarani M, et al. 2007. Dasatinib induces notable hematologic and cytogenetic responses in chronic phase chronic myeloid leukemia after failure of imatinib therapy. Blood, 109:2303-9.
-
(2007)
Blood
, vol.109
, pp. 2303-2309
-
-
Hochhaus, A.1
Kantarjian, H.M.2
Baccarani, M.3
-
20
-
-
0036850514
-
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy
-
Hochhaus A, Kreil S, Corbin AS, et al. 2002. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia, 16:2190-6.
-
(2002)
Leukemia
, vol.16
, pp. 2190-2196
-
-
Hochhaus, A.1
Kreil, S.2
Corbin, A.S.3
-
21
-
-
10744229080
-
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia
-
Hughes TP, Kaeda J, Branford S, et al. 2003. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med, 349:1423-32.
-
(2003)
N Engl J Med
, vol.349
, pp. 1423-1432
-
-
Hughes, T.P.1
Kaeda, J.2
Branford, S.3
-
22
-
-
33644838303
-
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment
-
Iacobucci I, Rosti G, Amabile M, et al. 2006. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. J Clin Oncol, 24:454-9.
-
(2006)
J Clin Oncol
, vol.24
, pp. 454-459
-
-
Iacobucci, I.1
Rosti, G.2
Amabile, M.3
-
23
-
-
34247403450
-
Preliminary activity of nilotinib (AMN107), a novel selective potent oral Bcr-Abl tyrosine kinase inhibitor, in newly diagnosed Philadelphia chromosome (Ph)-positive chronic phase chronic myelogenous leukemia (CML-CP)
-
Jabbour E, Cortes J, Giles F, et al. 2006. Preliminary activity of nilotinib (AMN107), a novel selective potent oral Bcr-Abl tyrosine kinase inhibitor, in newly diagnosed Philadelphia chromosome (Ph)-positive chronic phase chronic myelogenous leukemia (CML-CP). Blood (ASH Annual Meeting Abstracts), 108:2172.
-
(2006)
Blood (ASH Annual Meeting Abstracts)
, vol.108
, pp. 2172
-
-
Jabbour, E.1
Cortes, J.2
Giles, F.3
-
24
-
-
33745086350
-
Nilotinib in imatinib- resistant CML and Philadelphia chromosome-positive ALL
-
Kantarjian H, Giles F, Wunderle L, et al. 2006a. Nilotinib in imatinib- resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med, 354:2542-51.
-
(2006)
N Engl J Med
, vol.354
, pp. 2542-2551
-
-
Kantarjian, H.1
Giles, F.2
Wunderle, L.3
-
25
-
-
4644359704
-
Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon- alpha
-
Kantarjian HM, Cortes JE, O'Brien S, et al. 2004. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon- alpha. Blood, 104:1979-88.
-
(2004)
Blood
, vol.104
, pp. 1979-1988
-
-
Kantarjian, H.M.1
Cortes, J.E.2
O'Brien, S.3
-
26
-
-
33846812048
-
A phase ii study of nilotinib a novel tyrosine kinase inhibitor administered to imatinib-resistant or intolerant patients with chronic myelogenous leukemia (CML) in accelerated phase (AP)
-
Kantarjian HM, Gattermann N, Hochhaus A, et al. 2006b. A phase ii study of nilotinib a novel tyrosine kinase inhibitor administered to imatinib-resistant or intolerant patients with chronic myelogenous leukemia (CML) in accelerated phase (AP). Blood (ASH Annual Meeting Abstracts), 108:2169.
-
(2006)
Blood (ASH Annual Meeting Abstracts)
, vol.108
, pp. 2169
-
-
Kantarjian, H.M.1
Gattermann, N.2
Hochhaus, A.3
-
27
-
-
33748696341
-
Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia
-
Kantarjian HM, Talpaz M, O'Brien S, et al. 2006c. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood, 108:1835-40.
-
(2006)
Blood
, vol.108
, pp. 1835-1840
-
-
Kantarjian, H.M.1
Talpaz, M.2
O'Brien, S.3
-
28
-
-
22044442973
-
Tyrosine kinases as targets for cancer therapy
-
Krause DS, Van Etten RA. 2005. Tyrosine kinases as targets for cancer therapy. N Engl J Med, 353:172-87.
-
(2005)
N Engl J Med
, vol.353
, pp. 172-187
-
-
Krause, D.S.1
van Etten, R.A.2
-
29
-
-
33846814283
-
A phase ii study of nilotinib, a novel tyrosine kinase inhibitor administered to imatinib-resistant and -intolerant patients with chronic myelogenous leukemia (CML) in chronic phase (CP)
-
le Coutre P, Bhalla K, Giles F, et al. 2006. A phase ii study of nilotinib, a novel tyrosine kinase inhibitor administered to imatinib-resistant and -intolerant patients with chronic myelogenous leukemia (CML) in chronic phase (CP). Blood (ASH Annual Meeting Abstracts), 108:165.
-
(2006)
Blood (ASH Annual Meeting Abstracts)
, vol.108
, pp. 165
-
-
Coutre, P.1
Bhalla, K.2
Giles, F.3
-
30
-
-
33845723163
-
Dasatinib (BMS-354825) pharma-cokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure
-
Luo FR, Yang Z, Camuso A, et al. 2006. Dasatinib (BMS-354825) pharma-cokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure. Clin Cancer Res, 12:7180-6.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 7180-7186
-
-
Luo, F.R.1
Yang, Z.2
Camuso, A.3
-
31
-
-
33645509358
-
Fragmentation study of imatinib and characterization of new imatinib metabolites by liquid chromatography-triple- quadrupole and linear ion trap mass spectrometers
-
Marull M, Rochat B. 2006. Fragmentation study of imatinib and characterization of new imatinib metabolites by liquid chromatography-triple- quadrupole and linear ion trap mass spectrometers. J Mass Spectrom, 41:390-404.
-
(2006)
J Mass Spectrom
, vol.41
, pp. 390-404
-
-
Marull, M.1
Rochat, B.2
-
33
-
-
0037079720
-
Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro
-
Mow BM, Chandra J, Svingen PA, et al. 2002. Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood, 99:664-71.
-
(2002)
Blood
, vol.99
, pp. 664-671
-
-
Mow, B.M.1
Chandra, J.2
Svingen, P.A.3
-
34
-
-
9144253153
-
Dynamics of BCR- ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C
-
Muller MC, Gattermann N, Lahaye T, et al. 2003. Dynamics of BCR- ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C. Leukemia, 17:2392-400.
-
(2003)
Leukemia
, vol.17
, pp. 2392-2400
-
-
Muller, M.C.1
Gattermann, N.2
Lahaye, T.3
-
35
-
-
0037762632
-
Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia
-
O'Brien SG, Deininger MW. 2003. Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia. Semin Hematol, 40:26-30.
-
(2003)
Semin Hematol
, vol.40
, pp. 26-30
-
-
O'Brien, S.G.1
Deininger, M.W.2
-
36
-
-
30644462841
-
Targeted CML therapy: Controlling drug resistance, seeking cure
-
O'Hare T, Corbin AS, Druker BJ. 2006. Targeted CML therapy: controlling drug resistance, seeking cure. Curr Opin Genet Dev, 16:92-9.
-
(2006)
Curr Opin Genet Dev
, vol.16
, pp. 92-99
-
-
O'Hare, T.1
Corbin, A.S.2
Druker, B.J.3
-
37
-
-
21144451094
-
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants
-
O'Hare T, Walters DK, Stoffregen EP, et al. 2005. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res, 65:4500-5.
-
(2005)
Cancer Res
, vol.65
, pp. 4500-4505
-
-
O'Hare, T.1
Walters, D.K.2
Stoffregen, E.P.3
-
38
-
-
33750479897
-
Successful mobilization of Ph-negative blood stem cells with intensive chemo-therapy + G-CSF in patients with chronic myelogenous leukemia in first chronic phase
-
Olsson-Stromberg U, Hoglund M, Bjorkholm M, et al. 2006. Successful mobilization of Ph-negative blood stem cells with intensive chemo-therapy + G-CSF in patients with chronic myelogenous leukemia in first chronic phase. Leuk Lymphoma, 47:1768-73.
-
(2006)
Leuk Lymphoma
, vol.47
, pp. 1768-1773
-
-
Olsson-Stromberg, U.1
Hoglund, M.2
Bjorkholm, M.3
-
39
-
-
34247338940
-
A phase ii study of nilotinib, a novel tyrosine kinase inhibitor administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL)
-
Ottmann O, Kantarjian H, Larson R, et al. 2006. A phase ii study of nilotinib, a novel tyrosine kinase inhibitor administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL). Blood (ASH Annual Meeting Abstracts), 108:1862.
-
(2006)
Blood (ASH Annual Meeting Abstracts)
, vol.108
, pp. 1862
-
-
Ottmann, O.1
Kantarjian, H.2
Larson, R.3
-
40
-
-
23844553757
-
T315I-mutated Bcr-Abl in chronic myeloid leukemia and imatinib: Insights from a computational study
-
Pricl S, Fermeglia M, Ferrone, et al. 2005. T315I-mutated Bcr-Abl in chronic myeloid leukemia and imatinib: insights from a computational study. Mol Cancer Ther, 4:1167-74.
-
(2005)
Mol Cancer Ther
, vol.4
, pp. 1167-1174
-
-
Pricl, S.1
Fermeglia, M.2
Ferrone3
-
41
-
-
33846200681
-
Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure
-
Quintas-Cardama A, Kantarjian H, et al. 2007. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood, 109:497-9.
-
(2007)
Blood
, vol.109
, pp. 497-499
-
-
Quintas-Cardama, A.1
Kantarjian, H.2
-
42
-
-
79959308232
-
Loss of response to imatinib: Mechanisms and management
-
Shah NP. 2005. Loss of response to imatinib: mechanisms and management. Hematology (Am Soc Hematol Educ Program), 183-7.
-
(2005)
Hematology (Am Soc Hematol Educ Program)
, pp. 183-187
-
-
Shah, N.P.1
-
43
-
-
33845254606
-
Improving upon the promise of targeted therapy of human malignancy: Chronic myeloid leukemia as a paradigm
-
Shah NP. 2006. Improving upon the promise of targeted therapy of human malignancy: chronic myeloid leukemia as a paradigm. Cancer Chem-other Pharmacol, 58(Suppl 7):49-53.
-
(2006)
Cancer Chem-other Pharmacol
, vol.58
, Issue.7 SUPPL.
, pp. 49-53
-
-
Shah, N.P.1
-
44
-
-
0001686739
-
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
-
Shah NP, Nicoll JM, Nagar B, et al. 2002. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell, 2:117-25.
-
(2002)
Cancer Cell
, vol.2
, pp. 117-125
-
-
Shah, N.P.1
Nicoll, J.M.2
Nagar, B.3
-
45
-
-
33846228789
-
Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia
-
Soverini S, Colarossi S, Gnani, et al. 2006. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res, 12:7374-9.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 7374-7379
-
-
Soverini, S.1
Colarossi, S.2
Gnani3
-
46
-
-
23044458596
-
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: A study by the GIMEMA Working Party on Chronic Myeloid Leukemia
-
Soverini S, Martinelli G, Rosti, et al. 2005. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol, 23:4100-9.
-
(2005)
J Clin Oncol
, vol.23
, pp. 4100-4109
-
-
Soverini, S.1
Martinelli, G.2
Rosti3
-
47
-
-
33745102555
-
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
-
Talpaz M, Shah NP, Kantarjian H, et al. 2006. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med, 354:2531-41.
-
(2006)
N Engl J Med
, vol.354
, pp. 2531-2541
-
-
Talpaz, M.1
Shah, N.P.2
Kantarjian, H.3
-
48
-
-
24644464172
-
AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells
-
Verstovsek S, Golemovic M, Kantarjian H, et al. 2005. AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. Cancer, 104:1230-6.
-
(2005)
Cancer
, vol.104
, pp. 1230-1236
-
-
Verstovsek, S.1
Golemovic, M.2
Kantarjian, H.3
-
49
-
-
33745114173
-
AMN107 (nilotinib): A novel and selective inhibitor of BCR-ABL
-
Weisberg E, Manley P, Mestan J, et al. 2006. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer, 94:1765-9.
-
(2006)
Br J Cancer
, vol.94
, pp. 1765-1769
-
-
Weisberg, E.1
Manley, P.2
Mestan, J.3
-
50
-
-
33745085275
-
OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilo-tinib (AMN107): Reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib
-
White DL, Saunders VA, Dang P, et al. 2006. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilo-tinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood, 108:697-704.
-
(2006)
Blood
, vol.108
, pp. 697-704
-
-
White, D.L.1
Saunders, V.A.2
Dang, P.3
|